Tenax Therapeutics, Inc.
NASDAQ:TENXBiotechnology
+$0.10 today
- Market cap
- $50.66M
- Beta
- 0.97
- P/E (TTM)
- -9.4
- EPS (TTM)
- -$1.28
Volume 0.70M
Average 0.62M
TENX Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Tenax Therapeutics, Inc.NASDAQ: TENX
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$118.76M, compared with -$111.45M a year earlier.
Context
- Net debt amounted to 96.4% of total assets at the end of Q1 FY2026, down 3.0 pp from a year earlier.
- Net debt grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net debt keeps falling in the next quarterly balance sheet after a -6.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (97.57M) USD
- Year-over-year change
- -2.9%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (97.57M) | -2.9% |
| FY2024 | 2024-12-31 | (94.85M) | -920.9% |
| FY2023 | 2023-12-31 | (9.29M) | -606.1% |
| FY2022 | 2022-12-31 | (1.32M) | +75.1% |
| FY2021 | 2021-12-31 | (5.29M) | — |
Net Debt vs competitors
How TENX compares with its peers on the latest reported figures
- TENX's Mar 2026 net debt of -$118.76M is the 6th highest of the 7 companies compared; the peer median is -$29.46M.
- Its year-over-year change of -6.6% is the 2nd highest of 7, against a peer median of -191.3%.
- Net debt amounts to 96.4% of total assets for TENX, versus a peer median of 37.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $30.81M | -7.9% | — | 21.9% | |
| Jun 2026 | -$3.14M | -215.0% | — | 1.3% | |
| Mar 2026 | -$19.16M | -249.2% | — | 49.4% | |
| Mar 2026 | -$39.76M | +14.8% | — | 62.4% | |
| Mar 2026 | -$53.49M | -167.6% | — | 61.1% | |
| Mar 2026 | -$118.76M | -6.6% | — | 96.4% | |
| Jun 2026 | -$24.58B | -161104.7% | — | 25.8% | |
| Peer median (excluding TENX) | -$29.46M | -191.3% | — | 37.6% | |
Competitors are the stored peer set for TENX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Tenax Therapeutics, Inc.
NASDAQ:TENX
Intrinsic Alpha fair value
Locked
Current Price
$1.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.